Validation of Vemurafenib in Previously Treated BRAF V600 – Mutated Metastatic Melanoma: BRIM 2 Update

Vemurafenib (PLX4032) is a next generation oral BRAF inhibitor for the treatment of metastatic melanoma harbouring the BRAF V600 mutation. Update from the BRIM 2 trial on previously treated patients has shown that 53% of the patients experienced tumor shrinkage (95% confidence interval [CI], 44 to 62; 6% with complete responses and 47% with partial responses). The median progression-free survival was 6.8 months (95% CI, 5.6 to 8.1). Primary progression was observed in only 14% of patients. Furthermore, some patients had a response after receiving Vemurafenib for more than 6 months. The median overall survival was 15.9 months (95% CI, 11.6 to 18.3).

I like this approach because it shows us how effective targeted approaches can be. But more importantly, because they selectively target tumor cells, they do not produce the adverse effects of chemo/radiation therapy.

Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib.


Speak Your Mind